Products & Pipeline

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

GW has been researching cannabinoids since 1998 and has established a world leading position in the development of plant-derived cannabinoid therapeutics through our proven drug discovery and development processes, our intellectual property portfolio and our regulatory and manufacturing expertise. GW’s research explores the potential therapeutic application of cannabinoids and we have evaluated the pharmacology of a number of cannabinoids across a wide range of disease areas.

Our primary focus is on disorders of the central nervous system (CNS) including epilepsy. Our lead cannabinoid product candidate is Epidiolex®, a liquid formulation of pure plant-derived cannabidiol, or CBD, which is in development for the treatment of a number of rare childhood-onset epilepsy disorders.

We commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in 30 countries outside the United States.

We have a deep pipeline of additional cannabinoid product candidates which include compounds in development for epilepsy, glioma and schizophrenia.

GW is in a unique position to develop and manufacture plant-derived cannabinoid formulations worldwide at sufficient quality, uniformity and scale for the purposes of pharmaceutical development and to meet international regulatory requirements.

Pharmaceutical Development Pipeline

  • Unpartnered
  • Partnered
  • Pre-Clinic
  • Phase 1
  • Phase 2
  • Phase 3
  • Submit
  • Approved


Dravet Syndrome
Lennox-Gastaut Syndrome
Tuberous Sclerosis
Phase 3
Infantile Spasms
Phase 2

CBDV (GWP42006)

GWP42006 (CBDV)
Phase 2
GWP42006 (CBDV)
Autism Spectrum Disorders
Phase 1


GWP42003 (IV)
Neonatal Hypoxic-ischemic Encephalopathy
Phase 1
GWP42002 / GWP42003
Completed Phase 2
Completed Phase 2

Sativex (Partnered)

Ms Spasticity

Recent Pipeline News

Nov 21, 2017
- Over 20 abstracts released online today from Phase 3 programs in Lennox-Gastaut Syndrome and Dravet syndrome and from Expanded Access Program -
Oct 30, 2017
London, UK and Carlsbad, CA, 30 Oct 2017: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S.